Related references
Note: Only part of the references are listed.Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso et al.
TARGETED ONCOLOGY (2021)
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Isabelle Ray-Coquard et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2019)
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies
Stephanie L. Gaillard et al.
GYNECOLOGIC ONCOLOGY (2019)
Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance
Mayra Tsoi et al.
FASEB JOURNAL (2019)
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote et al.
LANCET ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
Victor Rodriguez-Freixinos et al.
ESMO OPEN (2019)
Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
Yutaka Yoneoka et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Transition of Mesenchymal and Epithelial Cancer Cells Depends on alpha 1-4 Galactosyltransferase-Mediated Glycosphingolipids
Francis Jacob et al.
CANCER RESEARCH (2018)
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients
V. Heinzelmann-Schwarz et al.
GYNECOLOGIC ONCOLOGY (2018)
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
Ruth Plummer et al.
ADVANCES IN THERAPY (2018)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 24, pg 24, 2013)
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Endocrine therapy in epithelial ovarian cancer
Simon P. Langdon et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma
Piret Soovares et al.
GYNECOLOGIC ONCOLOGY (2017)
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis
Laura Paleari et al.
GYNECOLOGIC ONCOLOGY (2017)
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
David M. Gershenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Kristina Lindemann et al.
BRITISH JOURNAL OF CANCER (2017)
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N. Dickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ovarian Cancer, Version 1.2016
Robert J. Morgan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A. Ledermann et al.
LANCET (2016)
Expression of LATS family proteins in ovarian tumors and its significance
Bing Xu et al.
HUMAN PATHOLOGY (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
T. Bosse et al.
EUROPEAN JOURNAL OF CANCER (2014)
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Weiva Sieh et al.
LANCET ONCOLOGY (2013)
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2012)
Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum
Matthew P. Schlumbrecht et al.
MODERN PATHOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
Patrick Royston et al.
STATISTICS IN MEDICINE (2011)
The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer
Susana Banerjee
STEROIDS (2011)
Consolidation Therapy in Ovarian Cancer A Clinical Update
Paul Sabbatini
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
ZW Wong et al.
BRITISH JOURNAL OF CANCER (2004)
Share Paper
